What this page establishes
- Ozempic is licensed for type 2 diabetes, cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease, and kidney outcomes in type 2 diabetes with chronic kidney disease. Doses: 0.25, 0.5, 1 and 2 mg weekly.
- Wegovy is licensed for long-term weight reduction in adults and children 12 and over, and for cardiovascular risk reduction in established cardiovascular disease with obesity or overweight. Doses: 0.25, 0.5, 1, 1.7 and 2.4 mg weekly.
- Both labels state that coadministration with another semaglutide-containing product or any other GLP-1 receptor agonist is not recommended.
- Both carry a boxed warning for thyroid C-cell tumours observed in rodents.
Quick answers
Is Wegovy just a higher dose of Ozempic?
At the top of the range, yes: 2.4 mg versus 2 mg. Below that the two brands offer the same doses of the same molecule.
Read the full answer
The bigger difference is the licence, which is what determines whether a prescription is on-label and usually whether it is covered.Can I switch from Ozempic to Wegovy?
That is a prescribing decision and it depends on why you were on Ozempic. What the labels settle is that you do not take both, because they are the same drug and coadministration of two semaglutide products is specifically not recommended.
Read the full answer
Which one loses more weight?
There is no head-to-head trial of Ozempic against Wegovy, because a trial of a drug against itself at a slightly different dose would be answering a dose question.
Read the full answer
What exists is dose-response data for semaglutide, where higher doses produce more weight loss up to the studied ceiling.
Ozempic and Wegovy contain the same drug, semaglutide, made by the same company. Neither is a stronger version of the other in the sense people usually mean. What separates them is what each one is licensed to treat, and a difference of 0.4 mg at the top of the dose range.
What is actually different
Ozempic is licensed for type 2 diabetes, for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and established cardiovascular disease, and for kidney outcomes in type 2 diabetes with chronic kidney disease. Its dose range runs 0.25, 0.5, 1 and 2 mg once weekly.
Wegovy is licensed for long-term weight reduction in adults and in children aged 12 and over with obesity, for adults with overweight plus one weight-related condition, and for cardiovascular risk reduction in people with established cardiovascular disease and obesity or overweight. Its range runs 0.25, 0.5, 1, 1.7 and 2.4 mg once weekly.
So the licences barely overlap and the doses almost entirely do. Everything below 1.7 mg is a dose you can reach on either brand.
Why people are told Wegovy is stronger
Because at the top of each range it is, by 0.4 mg. That is the entire pharmacological difference between the two brands, and it only exists for someone titrated to the maximum of both.
The trials are the other reason. Ozempic was studied for glycaemic control and cardiovascular outcomes, Wegovy for weight. The weight-loss numbers people quote come from Wegovy trials because those are the trials that measured weight as the primary endpoint, not because the drug behaves differently.
The one thing both labels tell you not to do
Both labels carry the same limitation of use: do not coadminister with another semaglutide-containing product, or with any other GLP-1 receptor agonist. Running Ozempic and Wegovy together is stacking one drug on itself.
Both carry the same boxed warning for thyroid C-cell tumours, seen in rodents at clinically relevant exposures, with the human relevance unknown.
The evidence, one row per claim
| Claim | Tier | Source |
|---|---|---|
| Ozempic is licensed for type 2 diabetes, cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease, and kidney outcomes in type 2 diabetes with chronic kidney disease. Doses: 0.25, 0.5, 1 and 2 mg weekly. | established | FDA Structured Product Label, NDA209637 (via openFDA) |
| Wegovy is licensed for long-term weight reduction in adults and children 12 and over, and for cardiovascular risk reduction in established cardiovascular disease with obesity or overweight. Doses: 0.25, 0.5, 1, 1.7 and 2.4 mg weekly. | established | FDA Structured Product Label, NDA215256 (via openFDA) |
| Both labels state that coadministration with another semaglutide-containing product or any other GLP-1 receptor agonist is not recommended. | established | FDA Structured Product Label, NDA215256 (via openFDA) |
| Both carry a boxed warning for thyroid C-cell tumours observed in rodents. | established | FDA Structured Product Label, NDA209637 (via openFDA) |
Questions people ask
Why is Wegovy usually harder to get?
Supply and coverage, not chemistry. Weight-management indications are covered differently from diabetes indications by most insurers, and the two brands have had separate supply histories despite being the same molecule.
Sources
- FDA Structured Product Label, NDA209637 (via openFDA)
- FDA Structured Product Label, NDA215256 (via openFDA)
Keep reading
- Rybelsus vs Ozempic: The Tablet and the InjectionThe same drug taken two ways. The interesting part is what swallowing a peptide costs you.
- Ozempic vs Mounjaro: The Diabetes Head-to-HeadBoth are licensed for diabetes, and unusually for this category there is a randomised trial of one against the
- Wegovy vs Zepbound: The Head-to-Head Trial, and What It MeasuredMost brand comparisons infer from separate trials. This one has a randomised head-to-head, which makes it the